David G Nichols

Address:

6308 Silvery Star Path, Columbia, MD 21044

VIN:

2GCFK13Y471500043

Make:

CHEVROLET

Model:

SILVERADO 1500

Year:

2007

US Patent:

6916823, Jul 12, 2005

Filed:

Jan 16, 2002

Appl. No.:

10/050289

Inventors:

Richard B. Mailman - Chapel Hill NC, US
David E. Nichols - West Lafayette IN, US
Xuemei Huang - Chapel Hill NC, US

Assignee:

Purdue Research Foundation - West Lafayette IN
University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

A61K031/44

US Classification:

514284, 514285

Abstract:

The present invention relates to the treatment of dopamine-related dysfunction using full Ddopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “off-period. ” The Dagonist concentration is reduced during the “off-period” to obtain a plasma concentration of agonist that suboptimally activates Ddopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises the steps of periodically administering to a patient a full Dagonist with a half-life of up to about 6 hours at a dose resulting in a first plasma concentration of agonist capable of activating Ddopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 hours to obtain a second lower plasma concentration of agonist that results in suboptimal activation of Ddopamine receptors for a period of time sufficient to prevent induction of tolerance.

US Patent:

7768709, Aug 3, 2010

Filed:

Feb 3, 2006

Appl. No.:

11/346566

Inventors:

Fred F. Froehlich - Baltimore MD, US
David B. Nichols - Columbia MD, US

Assignee:

Northrop Grumman Systems Corporation - Los Angeles CA

International Classification:

G02B 27/30
G02B 27/10
H04J 14/00

US Classification:

359641, 359618, 398 53

Abstract:

An optical tapped delay line device in accordance with the present invention is a method for and device for spatially resolving the spectral components of an optical signal, i. e. , channelizing or spectrum analyzing the wavelength content of an optical signal. The device is based on a tapped optical delay line and enables numerous related optical signal processing functions.

US Patent:

8617166, Dec 31, 2013

Filed:

Nov 19, 2010

Appl. No.:

12/950061

Inventors:

Shaun B. Hanson - West Chester PA, US
Christopher D. Mandeen - Bethlehem PA, US
David L. Nichols - West Chester PA, US
Thomas A. Russell - Eads TN, US

Assignee:

Zimmer Knee Creations, Inc. - West Chester PA

International Classification:

A61F 2/46

US Classification:

606 86R, 606 88

Abstract:

An instrument for controlled delivery of a device to a target area near a defect of a bone is provided. The instrument comprises a guide frame having a plurality of device portals, each portal defining a trajectory. The guide frame further includes visual markers for aligning the guide frame to an anatomical landmark on the bone to be treated. The instrument also includes a holder for releasable attachment with the guide frame. Each device portal is configured to provide accurate and controlled delivery of the device to the target area. In one example, the markers are radiopaque, and are visualized through fluoroscopy. A method of using the instrument is also provided.

US Patent:

8623089, Jan 7, 2014

Filed:

Aug 7, 2012

Appl. No.:

13/568549

Inventors:

Peter F. Sharkey - Villanova PA, US
Charles F. Leinberry - Chester Springs PA, US
David L. Nichols - West Chester PA, US
Marc R. Viscogliosi - New York NY, US
Hallett Mathews - Williamsburg VA, US

Assignee:

Zimmer Knee Creations, Inc. - West Chester PA

International Classification:

A61F 2/44

US Classification:

623 1711, 606279

Abstract:

Methods for altering the natural history of degenerative disc disease and osteoarthritis of the spine are proposed. The methods focus on the prevention, or delayed onset or progression of, subchondral defects such as bone marrow edema or bone marrow lesion, and subchondral treatment to prevent the progression of osteoarthritis or degenerative disc disease in the spine and thereby treat pain.

US Patent:

20050232870, Oct 20, 2005

Filed:

Jun 13, 2005

Appl. No.:

11/151145

Inventors:

Richard Mailman - Chapel Hill NC, US
David Nichols - West Lafayette IN, US
Xuemei Huang - Chapel Hill NC, US

International Classification:

A61K031/137

US Classification:

424045000, 514649000

Abstract:

The present invention relates to the treatment of dopamine-related dysfunction using full Ddopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “off-period.” The Dagonist concentration is reduced during the “off-period” to obtain a plasma concentration of agonist that suboptimally activates Ddopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises the steps of periodically administering to a patient a full Dagonist with a half-life of up to about 6 hours at a dose resulting in a first plasma concentration of agonist capable of activating Ddopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 hours to obtain a second lower plasma concentration of agonist that results in suboptimal activation of Ddopamine receptors for a period of time sufficient to prevent induction of tolerance.

US Patent:

20070155720, Jul 5, 2007

Filed:

Dec 22, 2004

Appl. No.:

10/584019

Inventors:

Prabhavathi Fernandes - Chapel Hill NC, US
Richard Mailman - Chapel Hill NC, US
David Nichols - West Lafayette IN, US
Robert Postlethwait - Zionsville IN, US

Assignee:

DarPharma, Inc. - Chapel Hill NC

International Classification:

A61K 31/55
A61K 31/4745
A61K 31/473

US Classification:

514217020, 514291000, 514292000, 514298000, 514284000

Abstract:

Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine Dreceptor agonist, and administering to the patient an effective amount of a dopamine Dreceptor antagonist. Pharmaceutical compositions comprising a dopamine Dreceptor agonist and a dopamine Dreceptor antagonist are also described. The Ddopamine receptor agonist and the Ddopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

US Patent:

20070254906, Nov 1, 2007

Filed:

Jul 21, 2005

Appl. No.:

11/632874

Inventors:

Prabhavathi Fernandes - Chapel Hill NC, US
Richard Mailman - Chapel Hill NC, US
David Nichols - West Lafayette IN, US

Assignee:

DarPharma, Inc. - Chapel Hill NC

International Classification:

A61K 31/473
A61K 31/4741

US Classification:

514288000, 514284000

Abstract:

Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine Dreceptor agonist. Dopamine Dreceptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenyltetrahydrobenzazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.

US Patent:

20100041690, Feb 18, 2010

Filed:

Sep 11, 2009

Appl. No.:

12/558127

Inventors:

Prabhavathi B. Fernandes - Chapel Hill NC, US
Richard Bernard Mailman - Chapel Hill NC, US
David Earl Nichols - West Lafayette IN, US
Robert Niel Postlethwait - Zionsville IN, US

International Classification:

A61K 31/473
A61K 31/4741

US Classification:

514284, 514288

Abstract:

Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine Dreceptor agonist, and administering to the patient an effective amount of a dopamine Dreceptor antagonist, Pharmaceutical compositions comprising a dopamine Dreceptor agonist and a dopamine Dreceptor antagonist are also described. The Ddopamine receptor agonist and the Ddopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.